Zentalis Q2 net loss widens on higher R&D costs - ZNTL News | Rallies
Zentalis Q2 net loss widens on higher R&D costs Z ZNTL • 2026-08-06 Outlook
Zentalis expects DENALI Part 2 topline readout in 1H 2027 to support accelerated approval
ASPENOVA Phase 3 confirmatory trial is enrolling to support full approval in US and ex-US markets
Company says cash position is sufficient to fund operations into late 2027
Overview
Oncology drug developer's Q2 net loss widened as R&D expenses rose on trial milestones
Company completed enrollment in DENALI Part 2a and 2b, advancing accelerated approval strategy for azenosertib
Cash and equivalents totaled $174.6 mln at June 30, 2026, providing runway into late 2027
Result Drivers
Trial milestones - Increased R&D expenses driven by milestone payment for ASPENOVA Phase 3 trial commencement and higher clinical and manufacturing costsDENALI enrollment - Completion of enrollment in DENALI Part 2a and 2b supported advancement of accelerated approval strategy for azenosertibRegulatory engagement - Alignment with FDA on dose and study population maintained accelerated approval pathway for azenosertib Key Details and Analyst Coverage
Metric Beat/Miss Actual Consensus Estimate Q2 Loss Per Share $0.59
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $7.00, about 41.4% above its August 5 closing price of $4.95
•
2026-08-06
ZNTL•
